Related Experiment Video
Updated: Jul 5, 2025
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Clinical Significance and Expression Pattern of RIP5 and VGLL4 in Clear Cell Renal Cell Carcinoma Patients Treated
Tanja Tomić1, Davor Tomić2,3, Martina Vukoja3
1Faculty of Health Studies, University of Mostar, Bijeli Brijeg bb, 88000 Mostar, Bosnia and Herzegovina.
Abstract:
While clear cell renal cell carcinoma (ccRCC) is curable, advanced metastatic (mRCC) remains a clinical challenge. We analyzed clinical, pathohistological, and molecular data (Receptor Interacting Protein 5-RIP5 and Vestigial Like Family Member 4-VGLL4 expression) of 55 mRCC patients treated with first-line treatment with sunitinib. The trend of linear increase in the protein expression of RIP5 was observed with the progression of tumor grade. Overall, 80% of RIP5-positive cells were in the control kidneys and high-grade mRCC. On the contrary, RIP5 displayed low expression in grade 2 mRCC (5.63%). The trend of linear decrease in the expression of VGLL4 was observed with the progression of tumor grade. The highest protein expression of VGLL4 was observed in grade 2 (87.82%) in comparison to grade 3 and 4 and control. High expression of RIP5 mRNA was associated with longer first-line overall survival and longer progression-free survival in mRCC. In addition, a high VGLL4 mRNA expression showed better overall survival in patients with ccRCC. In conclusion, high mRNA expression of RIP5 and VGLL4 are important markers of better survival rates in mRCC patients.
Insights
Receptor Interacting Protein 5 (RIP5) and Vestigial Like Family Member 4 (VGLL4) mRNA expression levels are key indicators for improved survival in metastatic renal cell carcinoma (mRCC) patients treated with sunitinib.
Area of Science:
- Oncology
- Molecular Biology
- Pathology
Background:
- Metastatic clear cell renal cell carcinoma (mRCC) presents a significant clinical challenge despite curable early-stage disease.
- Sunitinib is a common first-line treatment for mRCC, but predicting patient outcomes remains crucial.
Purpose of the Study:
- To investigate the prognostic value of Receptor Interacting Protein 5 (RIP5) and Vestigial Like Family Member 4 (VGLL4) expression in mRCC patients.
- To correlate RIP5 and VGLL4 expression with tumor grade and patient survival outcomes.
Main Methods:
- Analysis of clinical, pathohistological, and molecular data from 55 mRCC patients receiving first-line sunitinib.
- Assessment of RIP5 and VGLL4 protein and mRNA expression levels in relation to tumor grade and survival.
Main Results:
- RIP5 protein expression increased with tumor grade, while VGLL4 protein expression decreased.
- High RIP5 mRNA expression correlated with longer overall survival (OS) and progression-free survival (PFS).
- High VGLL4 mRNA expression was associated with better OS in ccRCC patients.
Conclusions:
- High mRNA expression of RIP5 and VGLL4 are significant biomarkers for predicting better survival in mRCC patients.
- These findings may aid in personalizing treatment strategies for mRCC.
Related Concept Videos
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:23Abnormal Proliferation
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...